Search Results

While most B-cell lymphomas are cured by chemotherapy, in recent years research interest has focused on the development of monoclonal antibodies and small molecules targeting membrane proteins, components of signaling pathways or tumor microenvironment, which are factors essential for the development and progression of lymphomas. Some of these new drugs have shown substantial clinical activity in phase I and small phase II studies in patients with relapsed and refractory disease, with response rates of up to 50-60% in some cases. These results give hope for patients who have standard treatment failure; however, their incorporation into commonly used regimens also represents a significant challenge for the future.
Antibodies, Monoclonal ; B-Lymphocytes* ; Drug Therapy ; Hope ; Humans ; Lymphoma ; Lymphoma, B-Cell ; Lymphoma, Non-Hodgkin* ; Membrane Proteins ; Treatment Failure ; Tumor Microenvironment

1.Ischemic colitis proximal to obstructing carcinoma of left colon: a report of one case report.

2.A case of myasthenia gravis in pregnancy.

3.Dermographic change of aging female population in Korea.

4.Dermographic change of aging female population in Korea.

5.A study on the regional blood flow of the hand.

6.An experimental study & clinical appliance of EMLA(eutectic mixture of local anesthetics).

7.Calcification in lung cancer: CT evaluation.

8.Otogenic cerebellar abscess: report of a case.

9.A case of leiomyoma occurred in scalp of retroauricular area.

10.Recently Developed Therapeutic Agents for B-cell Non-Hodgkin Lymphoma.

Display Mode

Output Records

File Type